Tonix Pharmaceuticals Holding Corp. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

FAIR VALUE MEASUREMENTS (Tables)

FAIR VALUE MEASUREMENTS (Tables)

12 Months Ended

Dec. 31, 2017

Schedule of financial assets measured at fair value on a recurring basis

The following table summarizes the Company’s financial assets measured at fair value on a recurring basis as of December 31, 2017 (in thousands):

Description	December 31, 2017		Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)
Assets:
Cash equivalents	$	17,349	$	17,349	$	—
Marketable securities – available for sale		-		-		-

Total assets	$	17,349	$	17,349	$	-

The following table summarizes the Company’s financial assets measured at fair value on a recurring basis as of December 31, 2016 (in thousands):

Description	December 31, 2016		Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)
Assets:
Cash equivalents	$	10,006	$	10,006	$	—
Marketable securities – available for sale		7,180		5,926		1,254

Total assets	$	17,186	$	15,932	$	1,254

Schedule of reconciliation of cash, cash equivalents and restricted cash

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statement of cash flow:

	December 31,
	2017		2016
	(in thousands)

Cash and cash equivalents	$	25,496	$	18,941
Restricted cash included in Other assets		89		89
Total	$	25,585	$	19,030